FDA asks about regulating foreign firms more and destroying drugs at the border, and questions firms about particles and aseptic practices.

Pharmacy benefit management has historically driven drug costs lower, at least in part by cutting dispensing fees and minimizing the pharmacist's role in managed care decision-making. But Mim is turning that around, using pharmacists' unique role in the dispensing episode to push higher-than-industry-norm levels of generic substitution.